Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: A double-blind, randomized, placebo-controlled trial

Journal of the American Academy of Dermatology

Volumn 48, Issue 4, 2003, Pages 535-541

  Monroe, Eugene ^a   Finn, Albert ^b   Patel, Piyush ^c   Guerrero, Robinson ^d   Ratner, Paul ^e   Bernstein, David ^f   Cohen, Robert M ^g   Falliers, Constantine John ^g   Finn Jr , Albert F ^g   Hampel, Frank C ^g   Heller, Alan M ^g   Perin, Patrick V ^g   Rowe, Michael S ^g   Sim, Tommy Chua ^g   Miller, D Lee ^g   Grubbe, Robert E ^g   Berger, William ^g   Baker, James ^g   Raimer, Sharon A ^g   Hamlin, Regina ^g   Stricker, William ^g   Van Bavel, Julius H ^g   Bucko, Alicia D ^g   Lynde, Charles ^g   Moote, Bill ^g   Sanchez, Mario ^g   Sussman, Gordon L ^g   Ring, Johannes ^g   Fierlbeck, Gerhardt ^g   Ruzicka, Thomas ^g   Holst, Tormod ^g   Hornmark, Ann Marie ^g   Ceuppens, Jan ^g   more..

^a Advanced Healthcare   (United States)

^b National Allergy   (United States)

^c Allied Clinical Research   (Canada)

^d Ctro de Enferm Resp y Dermatol   (Chile)

^e Sylvana Research   (United States)

^f Bernstein Allergy Group   (United States)

^g Milwaukee Medical Clinic ^*

Author keywords

[No Author keywords available]

Indexed keywords

DESLORATADINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BRONCHITIS; CHRONIC URTICARIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; IDIOPATHIC DISEASE; INCIDENCE; MALE; MEDICAL ASSESSMENT; MULTICENTER STUDY; NAUSEA; PARALLEL DESIGN; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SCORING SYSTEM; SEDATION; SIDE EFFECT; SINUSITIS; SLEEP DISORDER; SOMNOLENCE; STATISTICAL SIGNIFICANCE; SYMPTOM; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VOMITING; XEROSTOMIA;

EID: 0037380546     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/mjd.2003.143     Document Type: Article

References (17)

1. Greaves MW. Chronic urticaria. N Engl J Med 1995;332:1767-72.
2. Champion RH. Urticaria: then and now. Br J Dermatol 1988;119:427-36.
3. Sabroe RA, Greaves MW. The pathogenesis of chronic idiopathic urticaria. Arch Dermatol 1997;133:1003-8.
4. Grattan CE, Boon AP, Eady RA, Winkelmann RK. The pathology of the autologous serum skin test response in chronic urticaria resembles IgE-mediated late-phase reactions. Int Arch Allergy Appl Immunol 1990;93:198-204.
5. Kaplan AP, Horakova Z, Katz SI. Assessment of tissue fluid histamine levels in patients with urticaria. J Allergy Clin Immunol 1978;61:350-4.
6. Maxwell DL, Atkinson BA, Spur BW, Lessof MH, Lee TH. Skin responses to intradermal histamine and leukotrienes C4, D4, and E4 in patients with chronic idiopathic urticaria and in normal subjects. J Allergy Clin Immunol 1990;86:759-65.
7. Barlow RJ, Ross EL, MacDonald D, Black AK, Greaves MW. Adhesion molecule expression and the inflammatory cell infiltrate in delayed pressure urticaria. Br J Dermatol 1994;131:341-7.
8. Hide M, Francis DM, Grattan CE, Hakimi J, Kochan JP, Greaves MW. Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med 1993;328:1599-604.
9. Grattan CE, Francis DM, Hide M, Greaves MW. Detection of circulating histamine releasing autoantibodies with functional properties of anti-IgE in chronic urticaria. Clin Exp Allergy 1991;21:695-704.
10. Greaves M. Chronic urticaria. J Allergy Clin Immunol 2000;105:664-72.
11. 1-receptor antagonist drugs. J Allergy Clin Immunol 1996;98:S307-S318.
12. 1 receptor antagonist. 1st communication: receptor selectivity, antihistaminic activity, and antiallergenic effects. Arzneimittelforschung 2000;50:345-52.
13. 1 receptor antagonist: 2nd communication: lack of central nervous system and cardiovascular effects. Arzneimittelforschung 2000;50:441-8.
14. 1-receptor antagonist, in patients with seasonal allergic rhinitis: assessment during the spring and fall allergy seasons. Clin Drug Invest 2001;21:25-32.
15. Marino M, Glue P, Herron JM, Statkevich P, Affrime MB, Lim J. Lack of electrocardiographic effects of multiple high doses of desloratadine [abstract]. Allergy 2000;55(Suppl 63):279.
16. Glue P, Banfield C, Affrime MB, Statkevich P, Reyderman L, Padhi D, et al. Lack of electrocardiographic interaction between desloratadine and erythromycin [abstract]. Allergy 2000;55(Suppl 63):276.
17. Affrime MB, Banfield C, Glue P, Ngo LY, Keung A, Herron JM, et al. Lack of electrocardiographic effects when desloratadine and ketoconazole are coadministered [abstract]. Allergy 2000;55(Suppl 63):277.